Latest & greatest articles for lisinopril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lisinopril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lisinopril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lisinopril

1. Lisinopril

Lisinopril Top results for lisinopril - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lisinopril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients

Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or non-black patients Article Text Therapeutics Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive

Evidence-Based Medicine (Requires free registration)2006

3. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. CONTEXT: Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs). OBJECTIVE: To determine whether an ACE inhibitor or CCB is superior to a thiazide-type diuretic in reducing cardiovascular disease (CVD) incidence in racial subgroups. DESIGN, SETTING, AND PARTICIPANTS (...) : Prespecified subgroup analysis of ALLHAT, a randomized, double-blind, active-controlled, clinical outcome trial conducted between February 1994 and March 2002 in 33,357 hypertensive US and Canadian patients aged 55 years or older (35% black) with at least 1 other cardiovascular risk factor. INTERVENTIONS: Antihypertensive regimens initiated with a CCB (amlodipine) or an ACE inhibitor (lisinopril) vs a thiazide-type diuretic (chlorthalidone). Other medications were added to achieve goal blood pressures (BPs

JAMA2005

4. Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension

Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Article Text Therapeutics Amlodipine or lisinopril was not better than chlorthalidone in lowering CHD risk in hypertension Free Bruce M Psaty , MD, PhD Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2004

5. High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial

High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial High-versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart (...) failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial Schwartz J S, Wang Y R, Cleland J G, Gao L L, Weiner M, Poole-Wilson P A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Patients

NHS Economic Evaluation Database.2003

6. Economic evaluation of high vs low dosage lisinopril in patients with chronic heart failure

Economic evaluation of high vs low dosage lisinopril in patients with chronic heart failure Economic evaluation of high vs low dosage lisinopril in patients with chronic heart failure Economic evaluation of high vs low dosage lisinopril in patients with chronic heart failure Scalone L, Mantovani L T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions under study were two different dosages of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor for the treatment of patients with chronic heart failure (CHF): high-dosage lisinopril (32.5-35 mg/day) versus low-dose lisinopril (2.5-5 mg/day). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

NHS Economic Evaluation Database.2002

7. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.

Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. 11141144 2001 03 22 2001 04 05 2014 06 15 0959-8138 322 7277 2001 Jan 06 BMJ (Clinical research ed.) BMJ Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. 19-22 To determine the efficacy of an angiotensin converting enzyme inhibitor in the prophylaxis of migraine (...) . Double blind, placebo controlled, crossover study. Neurological outpatient clinic. Sixty patients aged 19-59 years with migraine with two to six episodes a month. Treatment period of 12 weeks with one 10 mg lisinopril tablet once daily for one week then two 10 mg lisinopril tablets once daily for 11 weeks, followed by a two week wash out period. Second treatment period of one placebo tablet once daily for one week and then two placebo tablets for 11 weeks. Thirty participants followed this schedule

BMJ2001 Full Text: Link to full Text with Trip Pro

8. Cost-effectiveness analysis of early treatment with lisinopril for patients with acute myocardial infarction: results from the GISSI-3 Trial

Cost-effectiveness analysis of early treatment with lisinopril for patients with acute myocardial infarction: results from the GISSI-3 Trial Cost-effectiveness analysis of early treatment with lisinopril for patients with acute myocardial infarction: results from the GISSI-3 Trial Cost-effectiveness analysis of early treatment with lisinopril for patients with acute myocardial infarction: results from the GISSI-3 Trial Franzosi M G, Maggioni A P, Santoro E, Tognoni G, Cavalieri E Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology examined in the study was lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, for the early (within 24 hours) treatment of acute myocardial infarction (MI). Type of intervention

NHS Economic Evaluation Database.2000

9. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study

Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study Low doses vs. high doses of the angiotensin (...) converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study Sculpher M J, Poole L, Cleland J, Drummond M, Armstrong P W, Horowitz J D, Massie B M, Poole-Wilson P A, Ryden L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2000

10. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. 10968433 2000 09 20 2000 09 20 2016 11 24 0140-6736 356 9230 2000 Aug 19 Lancet (London, England) Lancet Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. 615-20 We aimed to assess in patients with congestive heart (...) failure whether dual inhibition of neutral endopeptidase and angiotensin-converting enzyme (ACE) with the vasopeptidase inhibitor omapatrilat is better than ACE inhibition alone with lisinopril on functional capacity and clinical outcome. We did a prospective, randomised, double-blind, parallel trial of 573 patients with New York Heart Association (NYHA) class II-IV congestive heart failure, left-ventricular ejection fraction of 40% or less, and receiving an ACE inhibitor. Patients were randomly assigned

Lancet2000

11. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. 11110735 2000 12 29 2001 02 15 2014 06 15 0959-8138 321 7274 2000 Dec 09 BMJ (Clinical research ed.) BMJ Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan (...) and lisinopril microalbuminuria (CALM) study. 1440-4 To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment. Tertiary hospitals and primary care centres in four

BMJ2000 Full Text: Link to full Text with Trip Pro

12. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. 9433426 1998 02 05 1998 02 05 2015 06 16 0140-6736 351 9095 1998 Jan 03 Lancet (London, England) Lancet Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin (...) -Dependent Diabetes Mellitus. 28-31 Retinopathy commonly occurs in people with type 1 diabetes. Strict glycaemic control can decrease development and progression of retinopathy only partially. Blood pressure is also a risk factor for microvascular complications. Antihypertensive therapy, especially with inhibitors of angiotensin-converting enzyme (ACE), can slow progression of nephropathy, but the effects on retinopathy have not been established. We investigated the effect of lisinopril on retinopathy in type 1 diabetes. As

Lancet1998

13. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.

Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. 9269212 1997 09 15 1997 09 15 2015 06 16 0140-6736 349 9068 1997 Jun 21 Lancet (London, England) Lancet Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. 1787-92 Renal disease in people with insulin (...) -dependent diabetes (IDDM) continues to pose a major health threat. Inhibitors of angiotensin-converting enzyme (ACE) slow the decline of renal function in advanced renal disease, but their effects at earlier stages are unclear, and the degree of albuminuria at which treatment should start is not known. We carried out a randomised, double-blind, placebo-controlled trial of the ACE inhibitor lisinopril in 530 men and women with IDDM aged 20-59 years with normoalbuminuria or microalbuminuria. Patients were

Lancet1997

14. Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension

Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension Conversions from captopril to lisinopril at a dosage ratio of 5:1 result in comparable control of hypertension Gill T H, Hauter F, Pelter M A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Continuing the use of captopril or switching to lisinopril therapy at an initial daily conversion ratio of captopril 5 mg to lisinopril 1 mg in patients with mild-to-moderate hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients suffering from mild

NHS Economic Evaluation Database.1996

15. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. 7910229 1994 06 10 1994 06 10 2015 06 16 0140-6736 343 8906 1994 May 07 Lancet (London, England) Lancet GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute (...) myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. 1115-22 GISSI-3 is a multicentre randomised clinical trial to assess the efficacy of lisinopril, transdermal glyceryl trinitrate (GTN), and their combination in improving survival and ventricular function after acute myocardial infarction (AMI). Between June, 1991, and July, 1993, 19,394 patients were randomised from 200 coronary care units in Italy. Eligible patients presented within 24 h of symptom onset and had

Lancet1994